Compare THRY & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | TMCI |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 120.4M |
| IPO Year | 2020 | 2021 |
| Metric | THRY | TMCI |
|---|---|---|
| Price | $3.92 | $3.50 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 6 |
| Target Price | ★ $9.33 | $4.77 |
| AVG Volume (30 Days) | ★ 1.0M | 509.2K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $785,015,000.00 | $212,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.18 |
| P/E Ratio | $39.25 | ★ N/A |
| Revenue Growth | N/A | ★ 1.59 |
| 52 Week Low | $1.91 | $1.17 |
| 52 Week High | $14.28 | $7.78 |
| Indicator | THRY | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 83.55 |
| Support Level | $3.14 | $2.46 |
| Resistance Level | $4.17 | $7.08 |
| Average True Range (ATR) | 0.30 | 0.27 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 68.34 | 96.22 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.